Skip to content

Rapid Uptake Products (RUP)

As part of our support to the Accelerated Access Collaborative, AHSNs (through the AHSN Network) are driving adoption of a number of transformative technologies and medicines via the Rapid Uptake Products (RUP) programme.

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.

This year’s programme builds on the successes of the 2019/20 RUPs programme.

The following innovations will be supported through this year’s Rapid Uptake Products (RUP) Programme:

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath

FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

Access FeNO testing implementation resources here.

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors

The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).

How a heart attack saved a young mum’s life

In the latest Health Innovation Podcast from the AHSN Network, we speak to a fit and healthy 34-year-old mum who discusses how she had a heart attack while pregnant due to the genetic condition Familial Hypercholesterolaemia (FH), which creates an abnormal level of cholesterol in the blood. Our guest, Clara, talks to Dr Phil Jennings, AHSN Network Lead for the Rapid Uptake Products.

Listen to the Health Innovation Podcast now on Audioboom.

Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Around 1,400 people each year die from a severe asthma attack; and asthma deaths are 50 per cent more likely in poorest areas compared with the richest.

Now, people with severe asthma are being offered a newer type of treatment alongside their usual asthma medicines. These are known as monoclonal antibodies, also referred to as biologics.

Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks.

‘Game changer’ therapy for severe asthma sufferers

In the latest Health Innovation Podcast from the AHSN Network, we hear from a patient and a leading clinician on how biologics are a game changer for people whose lives have been blighted by asthma. Biologics are helping them to live normal lives – and reducing the risk of a fatal attack.

Listen to the Health Innovation Podcast now on Audioboom.

Funding available for Asthma biologics across the South West of England

Following a successful bid submitted by South West and West of England AHSNs to the Pathway Transformation Fund in April 2021, £129,000 funding has been awarded for the treatment of severe asthma. The Pathway Transformation Fund (PTF) is available to help NHS organisations integrate selected RUP into everyday practices and to overcome barriers to deploying them. The two AHSNs will be working alongside the South West Severe Asthma Network, Clinical Commissioning Groups and Acute Trusts.

Find out more about how your Asthma team can get involved in this work across the West of England and South West AHSN regions by contacting Clare Evans, Deputy Director of Service and System Transformation – clare.evans14@nhs.net or Rachel Gibbons, Senior Project Manager – rachel.gibbons10@nhs.net.

Rapid Uptake Product projects in our region

The Pathway Transformation Fund (PTF) is available to help NHS organisations integrate the Rapid Uptake Products into everyday practices. In the 2021 application round, PTF is supporting projects to deploy a severe asthma biologics pathway, measuring fractional exhaled nitric oxide (FeNO) concentration in asthma and a lipid management clinical pathway.

Four PTF applications have attracted funding in the West of England region.

Find out more about the RUP projects running (thanks to successful PTF applications) in our region.

Rapid Uptake Products 19/20: 

Three Rapid Uptake Products from the 2019/20 programme will continue through 2020/21:

  • Placental growth factor (PIGF) based tests to help rule out pre-eclampsia quickly so that pregnant women receive the most appropriate care. Read more about this life saving world-first test for pregnant women.
  • HeartFlow FFRCT – analysis which creates a 3D model of the coronary arteries to help clinicians to rapidly diagnose patients with suspected coronary artery disease from coronary CT angiography.
  • PCSK9 inhibitors – will continue as part of a wider Lipid Management workstream. PCSK9 inhibitors are for the treatment of very high cholesterol, and are used together with a statin-type cholesterol-lowering medicine, or for patients who are unable to take or tolerate a statin.

Contact us

If you would like to get involved in this programme please contact Clare Evans, Deputy Director of Service and System Transformation – clare.evans14@nhs.net or Rachel Gibbons, Senior Project Manager – rachel.gibbons10@nhs.net.